Literature DB >> 2968966

Immune suppression gene on HLA-Bw54-DR4-DRw53 haplotype controls nonresponsiveness in humans to hepatitis B surface antigen via CD8+ suppressor T cells.

H Watanabe1, S Matsushita, N Kamikawaji, K Hirayama, M Okumura, T Sasazuki.   

Abstract

The development of antiviral vaccines has been accelerated using monoclonal antibody and/or recombinant DNA techniques, the objective being to prevent grave viral infectious diseases, such as acquired immunodeficiency syndrome (AIDS), adult T-cell leukemia (ATL), and hepatitis B virus (HBV)-associated liver diseases. Certain proportions of individuals in the human population do not have any appreciable immune response to foreign antigens, either in cases of natural exposure or a planned immunization. Here we report that in the nonresponders to HB vaccine, there is an HLA-linked immune suppression gene for hepatitis B surface antigen (Is-HBsAg) controlling the nonresponsiveness to HBsAg through HBsAg-specific suppressor T cells. The Is-HBsAg is in strong linkage disequilibrium with the HLA-Bw54-DR4-DRw53 haplotype.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2968966     DOI: 10.1016/0198-8859(88)90047-x

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  10 in total

1.  Response to HBV vaccination in patients with severe liver disease. Absence of an HLA effect.

Authors:  D H Van Thiel; J S Gavaler
Journal:  Dig Dis Sci       Date:  1992-09       Impact factor: 3.199

2.  Non-responsiveness to hepatitis B surface antigen vaccines is not caused by defective antigen presentation or a lack of B7 co-stimulation.

Authors:  I Desombere; T Cao; Y Gijbels; G Leroux-Roels
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

3.  The cellular basis for lack of antibody response to hepatitis B vaccine in humans.

Authors:  E Egea; A Iglesias; M Salazar; C Morimoto; M S Kruskall; Z Awdeh; S F Schlossman; C A Alper; E J Yunis
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

4.  Normal HBsAg presentation and T-cell defect in the immune response of nonresponders.

Authors:  M Salazar; H Deulofeut; C Granja; R Deulofeut; D E Yunis; D Marcus-Bagley; Z Awdeh; C A Alper; E J Yunis
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

5.  Genetic variants within the MHC region are associated with immune responsiveness to childhood vaccinations.

Authors:  Berran Yucesoy; Yerkebulan Talzhanov; Victor J Johnson; Nevin W Wilson; Raymond E Biagini; Wei Wang; Bonnie Frye; David N Weissman; Dori R Germolec; Michael I Luster; Michael M Barmada
Journal:  Vaccine       Date:  2013-09-26       Impact factor: 3.641

6.  Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth.

Authors:  Yufeng Li; Rong Ni; Wei Song; Wenshuo Shao; Sadeep Shrestha; Sushma Ahmad; Coleen K Cunningham; Patricia M Flynn; Bill G Kapogiannis; Craig M Wilson; Jianming Tang
Journal:  Hum Genet       Date:  2009-07-14       Impact factor: 4.132

7.  Construction of exogenous multiple epitopes of helper T lymphocytes and DNA immunization of its chimeric plasmid with HBV pre-S2/S gene.

Authors:  Wen-Jun Gao; Xiao-Mou Peng; Dong-Ying Xie; Qi-Feng Xie; Zhi-Liang Gao; Ji-Lu Yao
Journal:  World J Gastroenterol       Date:  2004-10-15       Impact factor: 5.742

8.  Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients.

Authors:  Alicja E Grzegorzewska; Piotr M Wobszal; Adrianna Mostowska; Paweł P Jagodziński
Journal:  BMC Nephrol       Date:  2012-08-03       Impact factor: 2.388

9.  Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients.

Authors:  Alicja E Grzegorzewska
Journal:  Hepat Mon       Date:  2012-11-14       Impact factor: 0.660

10.  The immune response to hepatitis B vaccine in humans: inheritance patterns in families.

Authors:  M S Kruskall; C A Alper; Z Awdeh; E J Yunis; D Marcus-Bagley
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.